

REMARKS

The Office Action of June 9, 2006 has been carefully studied. The claims in the case remain 1, 9, 10, 12, 13, 17-24 and 28-30. No claims have yet to be allowed.

Referring now to the detailed action, on page 2 thereof, last paragraph, it is stated that the above identified claims are enabling for a method for treating skin photo damage but does not reasonably provide enablement for reversing skin photo damage. It is seen that the present amendment to claim 1 specifies that the method is one of treating skin photo damage, thereby placing this claim in allowable condition. Accordingly, since all the dependent claims are directly or indirectly dependent on claim 1, all the claims are allowable.

It is also seen that claim 1 is amended so as to change "perorally" to "orally", in order to comport with the term "orally" in the specification, for example on page 3, the third line of the SUMMARY OF THE INVENTION. Also the term "the active ingredient" is changed to "an active ingredient" so as to avoid any problem of antecedent basis on the one hand and to make it clear that the formulation is not necessarily restricted to only one active ingredient.

Claim 18 is also amended so as to include "capsules" as an additional form of the nutritional supplement, support for the term "capsule" being found, for example in original claim 5.

As for the assertion in the Office Action that the present invention is non-enabling for a method of reversing skin photo damage, attention is courteously invited to the examples starting on page 8 of the specification wherein various compositions are set forth which are contemplated for oral administration to patients. Example 9, in particular, provides a contemplated protocol for evaluating the effect of the method of the present invention. Thus, Applicants respectfully submit that the present application is enabling by virtue of examples which, at the very least, can be characterized as prophetic examples, if not working examples. Accordingly, Applicants do not acquiesce to the rejection and reserve the right to file a separate continuation application or the like with additional arguments and/or evidence regarding the reversal of skin photo damage.

In view of the above remarks, favorable reconsideration is courteously requested.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



I. William Millen, Reg. No. 19,544
Attorney(s) for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201
Direct Dial: 703-243-6333
Facsimile: 703-243-6410

Attorney Docket No.: EMIC-0055

Filed: September 8, 2006